Among 340,489 service members, Camp Lejeune veterans had higher PD odds: OR 1.70 (95% CI 1.39–2.07).
Limitation: water contained TCE plus other volatile organic compounds; TCE cannot be isolated as the sole causal agent.Occupational exposure resource
TCE exposure, Parkinson’s disease, and the medical record.
A concise guide to the current evidence and the documentation needed for an individualized medical-causation assessment.
Bottom line
Evidence of association. Individual analysis still required.
Human studies support an association between TCE-contaminated environments or occupational TCE exposure and Parkinson’s disease. Animal studies provide biologic plausibility. The evidence does not establish that TCE caused every individual case, and an exposure history alone is not a diagnosis or a complete causation opinion.
Download the PDFUpdated August 2026
Human evidence
What the research shows
Ever TCE exposure was associated with PD: OR 6.1 (95% CI 1.2–33).
Limitation: 99 twin pairs, few exposed subjects, and a wide confidence interval make the estimate imprecise.Pooled estimate for any TCE exposure: OR 1.8 (95% CI 0.9–3.7).
Limitation: the confidence interval included 1.0, and historical exposure reconstruction remains difficult.Biologic plausibility
How TCE could contribute
- Mitochondrial injury: chronic TCE exposure has impaired complex I activity in experimental models.
- Oxidative stress and neuroinflammation: animal studies report oxidative damage, microglial activation, and dopaminergic neuron loss.
- Protein handling and signaling: experimental work reports alpha-synuclein accumulation, endolysosomal dysfunction, reduced autophagy, and increased LRRK2 kinase activity.
Interpret carefully
Mechanistic plausibility is supportive evidence—not proof of individual causation. Camp Lejeune involved an exposure mixture, historical dose reconstruction is often uncertain, and long latency makes a complete chronology essential.
Medical record guide
Build the record around exposure, disease, and reasoning.
Document exposure
Identify the agent or product; worksite, tasks, dates, frequency, duration, routes, protective equipment, ventilation, spills, and corroborating industrial-hygiene or environmental records.
Establish the diagnosis
Collect neurology assessments, examination findings, progression, medication response, phenotype, imaging, DaTscan when performed, laboratory work, and therapy records.
Create the timeline
Connect first and peak exposure, last exposure, prodromal features, motor-symptom onset, first documentation, diagnosis, and subsequent clinical course.
Address alternatives
Evaluate family history, age, other solvents or pesticides, traumatic brain injury, medications, vascular disease, atypical syndromes, metals, and other relevant conditions.
Structure the opinion
State the causal question and certainty standard. Explain exposure evidence, temporality, magnitude and duration, mechanistic support, human evidence, competing causes, limitations, and the reasoned conclusion.
Clinical testing limitation
Blood or urine testing reflects recent exposure and generally cannot reconstruct a solvent dose from decades earlier. A normal current test does not rule out past exposure.
Selected references
Evidence base
- Goldman SM, et al. Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune. JAMA Neurology. 2023;80:673–681.
- Goldman SM, et al. Solvent exposures and Parkinson disease risk in twins. Annals of Neurology. 2012;71:776–784.
- Goldman SM, et al. Occupational Trichloroethylene Exposure and Parkinson’s Disease Risk. CDC Stacks, 2017.
- De Miranda BR, et al. TCE induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model. Neurobiology of Disease. 2021;153:105312.
- Liu M, et al. Trichloroethylene and Parkinson’s Disease: Risk Assessment. Molecular Neurobiology. 2018;55:6201–6214.
- Agency for Toxic Substances and Disease Registry. Toxicological Profile for Trichloroethylene. 2019.
Educational use only. This resource does not provide medical or legal advice and does not substitute for an individualized review of exposure evidence, medical records, and the applicable legal standard.
Referral process
Four steps from inquiry to opinion.
01 · Initial inquiry
Share the referral question, jurisdiction, deadlines, and parties for conflict review—without protected health information.
02 · Scope & engagement
Confirm the materials, requested work product, timing, and terms.
03 · Secure transfer
Provide records only through the approved secure channel after engagement.
04 · Review & opinion
Receive clear communication, a thorough analysis, and the agreed deliverable.
consults@ClinicalEvidenceResearch.com · 865-755-5171 · 301 S Peters Road, Knoxville, Tennessee 37923
Request a consultation